PMID- 26264674
OWN - NLM
STAT- MEDLINE
DCOM- 20160525
LR  - 20191210
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 56
IP  - 1
DP  - 2016 Jan
TI  - Pretransplant platelet transfusion refractoriness is not associated with platelet 
      nonengraftment in T-replete hematopoietic progenitor cell transplantation for 
      hematologic malignancies.
PG  - 164-9
LID - 10.1111/trf.13263 [doi]
AB  - BACKGROUND: Cellular engraftment after allogeneic hematopoietic progenitor cell 
      transplantation (HPCT) can be affected by pre-HPCT antibodies against donor human 
      leukocyte antigen (HLA; donor-specific antibodies [DSAs]), which are commonly 
      acquired by either pregnancy or transfusion. Issues regarding high assay 
      sensitivity and variable interpretation limit routine screening for DSAs. 
      Platelet (PLT) transfusion refractoriness (PTR) is relatively common in patients 
      with hematologic malignancies, and anti-HLA alloantibodies can be identified in 
      up to 20% of cases. For patients with PTR undergoing subsequent allogeneic HPCT, 
      however, the effect if any on subsequent PLT nonengraftment is unknown. STUDY 
      DESIGN AND METHODS: We conducted a retrospective study of 480 adults who 
      underwent T-replete HPCT for hematologic malignancy and compared the 
      posttransplantation clinical outcomes between patients who were PTR before HPCT 
      and those who were not. RESULTS: Multivariate analysis demonstrated that PTR was 
      not directly associated with PLT nonengraftment or graft failure, but did predict 
      for early intensive care unit admission, which was the only variable associated 
      with these outcomes (p < 0.0001). CONCLUSION: Our findings suggest that PTR 
      before HPCT identifies patients at higher risk of early clinical rather than 
      immunologic complications.
CI  - (c) 2015 AABB.
FAU - Scott, Ashleigh
AU  - Scott A
AD  - Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and 
      Women's Hospital, Herston.
AD  - Australian Red Cross Blood Service, Kelvin Grove.
AD  - Pathology Queensland, Herston.
FAU - Baidya, Shoma
AU  - Baidya S
AD  - Australian Red Cross Blood Service, Kelvin Grove.
FAU - Butler, Jason
AU  - Butler J
AD  - Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and 
      Women's Hospital, Herston.
FAU - Morris, Kirk
AU  - Morris K
AD  - Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and 
      Women's Hospital, Herston.
FAU - Thornton, Alycia
AU  - Thornton A
AD  - Pathology Queensland, Herston.
FAU - Kennedy, Glen A
AU  - Kennedy GA
AD  - Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and 
      Women's Hospital, Herston.
AD  - The University of Queensland, St Lucia, Queensland, Australia.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20150811
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow Diseases/immunology/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - HLA Antigens/*immunology
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Isoantibodies/*immunology
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/immunology/*therapy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myelodysplastic Syndromes/immunology/therapy
MH  - Myeloproliferative Disorders/immunology/therapy
MH  - *Platelet Transfusion
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology/*therapy
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2015/08/13 06:00
MHDA- 2016/05/26 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/05/05 00:00 [received]
PHST- 2015/07/08 00:00 [revised]
PHST- 2015/07/13 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2016/05/26 06:00 [medline]
AID - 10.1111/trf.13263 [doi]
PST - ppublish
SO  - Transfusion. 2016 Jan;56(1):164-9. doi: 10.1111/trf.13263. Epub 2015 Aug 11.